Stock Events

Nxera Pharma. 

$7.13
6
+$0+0% Thursday 15:23

Statistics

Day High
7
Day Low
7
52W High
13.43
52W Low
7
Volume
1,000
Avg. Volume
27
Mkt Cap
865.67M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

11
NOV
Earnings
 

Dividends

0%Dividend Yield
Jun 15
$0.02
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

11NovExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2023
Q1 2024
Q2 2024
Next
-25.39
-15.65
-5.92
3.82
Expected EPS
-0.043065972288
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SOLTF. It's not an investment recommendation.
Alphabet
78096
GOOGL
Apple
67979
AAPL
Microsoft
63406
MSFT
Amazon
59137
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a major player in the pharmaceutical industry, directly competing in various therapeutic areas covered by Nxera Pharma.
Merck
MRK
Mkt Cap300.25B
Merck operates globally in the pharmaceutical sector, offering products that compete with Nxera Pharma's range, especially in prescription drugs.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson offers a broad range of health products that compete across multiple segments, including those targeted by Nxera Pharma.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline competes in the pharmaceutical and healthcare sectors, with overlapping interests in medications and therapies.
Novartis
NVS
Mkt Cap244.75B
Novartis is known for its extensive research and development in pharmaceuticals, competing with Nxera Pharma in innovation and market share.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie competes in the global pharmaceutical market, particularly in areas of chronic diseases, directly challenging Nxera Pharma's product lines.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol-Myers Squibb is a key competitor in the pharmaceutical industry, with a strong presence in drug development and marketing.
Sanofi
SNY
Mkt Cap141.43B
Sanofi operates internationally, offering products that compete in the same therapeutic areas as Nxera Pharma.
Lilly(Eli) &
LLY
Mkt Cap864.43B
Eli Lilly and Company is a major pharmaceutical company with competitive products in the diabetes and cancer sectors, relevant to Nxera Pharma's interests.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap21.38B
Teva Pharmaceutical Industries is a global competitor, particularly in the generic pharmaceuticals market, impacting Nxera Pharma's market dynamics.

About

Pharmaceuticals: Generic
Health Technology
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Show more...
CEO
Shinichi Tamura
Employees
360
Country
JP
ISIN
JP3431300007

Listings

TSE
JP
4565.TSE
US
SOLTF
F
DE
JSS.F